Edwards Lifesciences Analyst Ratings
Edwards Lifesciences Outlines Vision For Growth At Investor Conference
Edwards Lifesciences Shares Are Trading Higher After Company Provided an Updated FY25 Guidance.
Edwards Lifesciences Expects 2025 Sales Of $5.6B-$6B Vs. Consensus Of $5.91B, With Adjusted EPS Of $2.40-$2.50 Versus Consensus Of $2.44, Reaffirms 2024 Constant Currency Sales Growth Guidance Of 8%-10%
(BSX) - Analyzing Boston Scientific's Short Interest
Price Over Earnings Overview: Medtronic
Stocks With Improving and Deteriorating 'TechniGrade' by Piper Sandler
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
A Glimpse Into The Expert Outlook On IDEXX Laboratories Through 5 Analysts
Cracking The Code: Understanding Analyst Reviews For Stryker
This Gap Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Stryker Analyst Ratings
IDEXX Laboratories Analyst Ratings
Peering Into GE HealthCare Techs's Recent Short Interest
10 Health Care Stocks With Whale Alerts In Today's Session
Catalyst Watch: November Jobs, OPEC+ Meeting, Marvell, Salesforce Earnings
Becton, Dickinson and Company 10-K Risk Factors Highlight Intensified Global Economic Pressures, Stricter Regulations, Evolving Cybersecurity Threats, Climate Change Impacts, Geopolitical Risks, And Expanded Focus On Competition, Healthcare Costs, And...
The Analyst Verdict: Edwards Lifesciences In The Eyes Of 17 Experts
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%